Table 2.
Contingency table analysis of baseline levels of biomarkers and their value in predicting disease control (complete or partial response, or stable disease > 12 weeks) vs. progressive disease with sunitinib treatment
| VEGF-A | VEGF-C | sVEGFR-2 | sVEGFR-3 | sKIT | |
|---|---|---|---|---|---|
| Area under ROC curve, % | 77.3 | 87.0 | 53.9 | 55.8 | 51.3 |
| ROC-derived cut-point (pg/mL) | 137.6 | 941.8 | 7,416 | 61,600 | 46,635 |
| Fisher's exact P-value | 0.0078 | 0.0012 | 0.1107 | 0.090 | 0.6887 |
| Relative risk | 2.571 | 4.714 | 1.950 | 1.929 | 1.273 |
| Sensitivity | 0.500 | 0.857 | 0.643 | 0.429 | 0.500 |
| Specificity | 1.000 | 0.818 | 0.727 | 0.909 | 0.636 |
| Accuracy | 0.720 | 0.840 | 0.680 | 0.640 | 0.560 |
| Positive predictive value | 1.000 | 0.857 | 0.750 | 0.857 | 0.636 |
| Negative predictive value | 0.611 | 0.818 | 0.615 | 0.556 | 0.500 |
ROC, receiver operating characteristic